Jervell and Lange-Nielsen syndrome presents with deafness and syncopal attacks. Prolongation of QT-duration was identified as a hallmark of the disease, which became the first "long-QT syndrome" (LQT-syndrome). Genetic studies revealed a mutation in a gene encoding a voltage potassium channel, which was called KVLQT1. When coexpressed with the correct accessory subunit, KVLQT1 was shown to generate a slowly activating component of the delayed rectifier potassium current (I Ks ) (1, 2).
The role of I Ks for cardiac action potential (AP) configuration has remained enigmatic for some time. I Ks -Blocker did not affect AP configuration in multicellular preparations of dog hearts, despite the fact that both compounds effectively block I Ks in ventricular myocytes (3). Thus, failure of I Ks -block to prolong AP duration (APD) must be the result of some peculiar properties of I Ks . The activation time constant of I Ks in dog ventricular myocytes is so slow that no I Ks was generated during the first 300 ms of voltage steps in the range of a cardiac APplateau (up to +30 mV). β-Adrenoceptorstimulation increases I Ks conductance and accelerates activation kinetics (3). Only under this condition, the channel generates sufficient current so that I Ks -blockade prolongs APD. Accordingly, pharmacological I Ks -block prolonged QT c in awake dogs and mimicked the phenotype of LQT-syndrome (3). Collectively, these results suggest that a certain amount of sympathetic tone is needed to activate enough I Ks to contribute to repolarization. The main findings of this seminal work in dogs was later confirmed in left ventricles from undiseased humans (4).
These findings are in stark contrast to results recently published in PNAS by Zhang et al. (5) . Here, baseline APD, i.e., in the absence of β-adrenoceptor stimulation, was markedly longer in human induced pluripotent stem cell-derived cardiomymocytes (hiPSC-CM) from patients with a LQT1 mutation than in cells from controls. At first glance, this finding could simply indicate that repolarization reserve in hiPSC-CM is profoundly different from native human ventricular cardiomyocytes, with a much larger impact of unstimulated I Ks compared with other potassium currents. However, this interpretation is at odds with the wellknown slow-activation kinetics of (even stimulated) I Ks (4) and solid data showing that effects of I Ks -block, even in the presence of β-adrenoceptorstimulation, are restricted to the late repolarization phase, whereas the initial AP phase remained unaffected. In the study by Zhang et al. (5), the AP prolongation, both in a patient-derived hiPSC-CM line and in hiPSC-CM in which I Ks was genetically suppressed, was associated with more positive AP amplitude and an elevated plateau phase. This result can only be explained by suppression of a very rapidly activated repolarizing current. Indeed, figure 5A of ref. 5 shows I Ks -blocker-sensitive currents in control hiPSC-CM that activate almost instantaneously, very different from classic I Ks .
Thus, we would like to raise a word of caution with regard to the interpretation that the difference between the patient-derived hiPSC-CM and controls in the study by Zhang et al. (5) were indeed a result of differences in I Ks and, conversely, indicate a role of I Ks in these cells. Such a conclusion would require a thorough explanation why I Ks expressed in hiPSC-CM should fundamentally differ from the well-characterized I Ks in native cardiomyocytes or heterologous expression systems.
